Want to see INBP full AI Analyst Report?
INBP Stock Chart & Stats
$0.34
$0.02(5.88%)
At close: 4:00 PM EST
$0.34
$0.02(5.88%)
Day’s Range― - ―
52-Week Range$0.14 - $0.42
Previous CloseN/A
Volume200.00
Average Volume (3M)15.15K
Market Cap
$5.12M
Enterprise Value$3.42M
Total Cash (Recent Filing)$5.83M
Total Debt (Recent Filing)$3.35M
Price to Earnings (P/E)―
Beta0.01
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding31,059,610
10 Day Avg. Volume31,065
30 Day Avg. Volume15,153
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.53
Price to Sales (P/S)0.20
P/FCF Ratio5.77
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue0.07
Enterprise Value/Gross Profit1.53
Enterprise Value/Ebitda61.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Integrated Contract Manufacturing And DistributionA dual business model (contract manufacturing plus product distribution) provides diversified, fee-based revenue streams and multiple customer touchpoints. That structural mix supports recurring manufacturing revenue while distribution margins offer complementary cash generation across economic cycles.
Conservative Balance Sheet And Low LeverageLow debt-to-equity gives the company financial flexibility to withstand revenue volatility, access credit at lower risk, and prioritize operational needs. This structural conservatism reduces refinancing pressure and supports stability across multiple quarters.
Positive Operating And Free Cash Flow (TTM)Sustained positive operating and free cash flow despite a net loss indicates the business can generate internal liquidity to fund operations and modest investment. Durable cash generation helps cover working capital and cushions the company during earnings downtimes.
Bears Say
Material Revenue Decline And Negative MarginsA sharp, multi-quarter revenue decline combined with a negative net margin signals structural demand or pricing pressure. Shrinking gross margins (from ~14.9% in 2021 to ~5.9% TTM) suggest lasting margin compression that undermines sustainable profitability and return on capital.
Negative Operating Profitability And Volatile PerformanceNegative EBIT/EBITDA and volatile operating results reduce the company’s ability to reinvest, pursue growth projects, or absorb shocks. Persistently weak operating earnings increase reliance on external funding and make multi-quarter recovery more uncertain.
Reliance On Amended Credit Facilities And Smaller Equipment FinancingDependence on credit rollovers and a reduced equipment line signals constrained internal capital for capex. The convertible nature and tighter facility sizing can raise financing cost or dilution risk and may limit the company’s ability to invest in capacity over the medium term.
Integrated BioPharma News
INBP FAQ
What was Integrated BioPharma Inc’s price range in the past 12 months?
Integrated BioPharma Inc lowest stock price was $0.14 and its highest was $0.42 in the past 12 months.
What is Integrated BioPharma Inc’s market cap?
Integrated BioPharma Inc’s market cap is $5.12M.
When is Integrated BioPharma Inc’s upcoming earnings report date?
Integrated BioPharma Inc’s upcoming earnings report date is Sep 30, 2026 which is in 74 days.
How were Integrated BioPharma Inc’s earnings last quarter?
Integrated BioPharma Inc released its earnings results on May 08, 2026. The company reported -$0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.027.
Is Integrated BioPharma Inc overvalued?
According to Wall Street analysts Integrated BioPharma Inc’s price is currently Overvalued.
Does Integrated BioPharma Inc pay dividends?
Integrated BioPharma Inc does not currently pay dividends.
What is Integrated BioPharma Inc’s EPS estimate?
Integrated BioPharma Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrated BioPharma Inc have?
Integrated BioPharma Inc has 31,059,610 shares outstanding.
What happened to Integrated BioPharma Inc’s price movement after its last earnings report?
Integrated BioPharma Inc reported an EPS of -$0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Integrated BioPharma Inc?
Currently, no hedge funds are holding shares in INBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Integrated BioPharma Inc
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment provides warehousing and fulfilment services; and distributes raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Technical Analysis
Natural Alternatives International
―
Sow Good
―
FitLife Brands
―
Bon Natural Life
―
Healthy Choice Wellness Corp. Class A
―